Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia
Clinical trial NCT05776004 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05776004
- Sponsor
- Eagle Pharmaceuticals, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-22
- Primary completion
- 2026-02-10
- Enrollment
- 276
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.